MRK
Neutral signalScored 2026-10-27 Drivers: Congress, trend, fundamentals. Moteurs : Congrès, tendance, fondamentaux.
Research, not advice.
À propos
Merck & Co., Inc.
- Nom
- Merck & Co., Inc.
- Secteur
- Healthcare
- Industrie
- Drug Manufacturers - General
- Bourse
- NYSE
- Capitalisation
- $363.3B
- Employés
- 74,000
- PDG
- Robert Davis
- Site web
- https://www.merck.com
- Marché
- ABBVAMGNAZNGILDJNJLLY
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Decouvert par les declarations du Congres
- Insiders
- —
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$22,395,959
Avg sell (VWAP, 90d window) $131.88 vs last close $141.82 (+7.5%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- —
- Liquidity
- Liquid $1,415,544,761/day · 20d vol
- Last synced
-
2026-10-28 09:40:38
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-08-13 | Guindo Chirfi | Sell · S S | 10,000 | $135.00 | ≈ $1,350,000 | Form 4 |
| 2026-08-12 | Zachary Jennifer | Sell · S S | 80,315 | $133.46 | ≈ $10,718,495 | Form 4 |
| 2026-08-12 | DeLuca Richard R. | Sell · S S | 600 | $132.04 | ≈ $79,222 | Form 4 |
| 2026-08-11 | DeLuca Richard R. | Sell · S S | 5,427 | $132.35 | ≈ $718,261 | Form 4 |
| 2026-08-10 | DeLuca Richard R. | Sell · S S | 20,784 | $130.43 | ≈ $2,710,951 | Form 4 |
| 2026-08-06 | DeLuca Richard R. | Sell · S S | 300 | $131.02 | ≈ $39,307 | Form 4 |
| 2026-08-06 | Guindo Chirfi | Sell · S S | 15,000 | $131.00 | ≈ $1,965,000 | Form 4 |
| 2026-08-05 | Maraldo David R. | Sell · S S | 2,686 | $128.72 | ≈ $345,736 | Form 4 |
| 2026-08-05 | Williams David Michael | Sell · S S | 34,705 | $128.77 | ≈ $4,468,987 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
| Date | Member | Side | Amount range | Filing |
|---|---|---|---|---|
| 2026-08-19 | Maria Elvira Salazar | Buy | $15,001 - $50,000 | Filing |
| 2026-08-19 | Maria Elvira Salazar | Buy | $15,001 - $50,000 | Filing |
| 2026-08-19 | Maria Elvira Salazar | Buy | $15,001 - $50,000 | Filing |
| 2026-08-07 | Ro Khanna | Buy | $15,001 - $50,000 | Filing |
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-09-24 | Maria Elvira Salazar | Sale | $1,001 - $15,000 |
| 2026-09-04 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2026-08-28 | Michael McCaul | Sale | $50,001 - $100,000 |
| 2026-08-19 | Maria Elvira Salazar | Purchase | $15,001 - $50,000 |
| 2026-08-19 | Maria Elvira Salazar | Purchase | $15,001 - $50,000 |
| 2026-08-19 | Maria Elvira Salazar | Purchase | $15,001 - $50,000 |
| 2026-08-07 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2026-02-04 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
| 2026-01-29 | Ro Khanna | Sale | $15,001 - $50,000 |
| 2026-01-13 | Michael T. McCaul | Sale | $15,001 - $50,000 |
| 2025-12-19 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2025-12-18 | Julie Johnson | Sale (Full) | $1,001 - $15,000 |
| 2025-11-18 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2025-11-13 | Julie Johnson | Sale (Partial) | $1,001 - $15,000 |
| 2025-09-29 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2025-09-23 | Val Hoyle | Sale (Full) | $1,001 - $15,000 |
| 2025-08-28 | Marjorie Taylor Greene | Purchase | $1,001 - $15,000 |
| 2025-08-14 | Julie Johnson | Sale (Partial) | $1,001 - $15,000 |
| 2025-08-05 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2025-08-04 | Lisa C. McClain | Sale (Full) | $1,001 - $15,000 |
| 2025-07-11 | Ritchie Torres | Sale (Full) | $1,001 - $15,000 |
| 2025-06-24 | Lisa C. McClain | Purchase | $1,001 - $15,000 |
| 2025-06-16 | Scott Franklin | Sale (Full) | $1,001 - $15,000 |
| 2025-06-13 | Julie Johnson | Purchase | $1,001 - $15,000 |
| 2025-05-30 | Gilbert Cisneros | Sale | $1,001 - $15,000 |
| 2025-05-19 | Michael T. McCaul | Purchase | $50,001 - $100,000 |
| 2025-05-15 | Robert P. Bresnahan | Sale (Full) | $15,001 - $50,000 |
| 2025-05-09 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2025-05-09 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2025-05-05 | Marjorie Taylor Greene | Purchase | $1,001 - $15,000 |
| 2025-04-29 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2025-04-21 | Bruce Westerman | Sale (Full) | $1,001 - $15,000 |
| 2025-04-17 | Jefferson Shreve | Sale (Full) | $15,001 - $50,000 |
| 2025-04-09 | Marjorie Taylor Greene | Purchase | $1,001 - $15,000 |
| 2025-04-08 | Robert P. Bresnahan | Purchase | $15,001 - $50,000 |
| 2025-04-02 | Michael T. McCaul | Purchase | $100,001 - $250,000 |
| 2025-03-31 | Gilbert Cisneros | Sale (Partial) | $15,001 - $50,000 |
| 2025-03-20 | Kelly Morrison | Sale (Partial) | $1,001 - $15,000 |
| 2025-03-19 | Sheri Biggs | Sale (Full) | $15,001 - $50,000 |
| 2025-03-03 | Bruce Westerman | Purchase | $1,001 - $15,000 |
| 2025-02-26 | Gilbert Cisneros | Purchase | $15,001 - $50,000 |
| 2025-02-25 | Robert P. Bresnahan | Sale (Full) | $15,001 - $50,000 |
| 2025-02-24 | Jefferson Shreve | Purchase | $15,001 - $50,000 |
| 2025-01-27 | Josh Gottheimer | Sale (Full) | $15,001 - $50,000 |
| 2025-01-24 | Gilbert Cisneros | Sale (Full) | $1,001 - $15,000 |
| 2025-01-17 | Julie Johnson | Purchase | $1,001 - $15,000 |
| 2025-01-16 | Byron Donalds | Sale (Full) | $1,001 - $15,000 |
| 2025-01-16 | Byron Donalds | Sale (Full) | $1,001 - $15,000 |
| 2025-01-15 | Jared Moskowitz | Sale (Full) | $1,001 - $15,000 |
| 2025-01-15 | Jared Moskowitz | Sale (Full) | $1,001 - $15,000 |
| 2025-01-10 | Keith Self | Sale | $1,001 - $15,000 |
| 2025-01-10 | Keith Self | Sale | $1,001 - $15,000 |
| 2024-11-08 | Jared Moskowitz | Purchase | $1,001 - $15,000 |
| 2024-10-29 | Val Hoyle | Purchase | $1,001 - $15,000 |
| 2024-10-14 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2024-10-09 | Michael T. McCaul | Sale | $50,001 - $100,000 |
| 2024-10-09 | Michael T. McCaul | Sale | $1,001 - $15,000 |
| 2024-09-26 | Ritchie Torres | Purchase | $1,001 - $15,000 |
| 2024-09-24 | Jonathan Jackson | Sale (Full) | $15,001 - $50,000 |
| 2024-09-09 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2024-09-09 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2024-09-09 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2024-09-04 | John James | Sale (Full) | $1,001 - $15,000 |
| 2024-08-07 | Scott Franklin | Purchase | $1,001 - $15,000 |
| 2024-08-02 | Scott Franklin | Purchase | $1,001 - $15,000 |
| 2024-07-02 | Kathy E. Manning | Purchase | $1,001 - $15,000 |
| 2024-06-21 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2024-04-10 | Michael C. Burgess | Sale (Partial) | $1,001 - $15,000 |
| 2024-02-23 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2024-02-20 | Michael T. McCaul | Sale | $1,001 - $15,000 |
| 2024-02-20 | Michael T. McCaul | Sale | $1,001 - $15,000 |
| 2024-01-23 | Kathy E. Manning | Purchase | $15,001 - $50,000 |
| 2024-01-23 | Kathy E. Manning | Purchase | $1,001 - $15,000 |
| 2024-01-10 | Ro Khanna | Purchase | $15,001 - $50,000 |
| 2024-01-10 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-12-28 | Jared Moskowitz | Purchase | $1,001 - $15,000 |
| 2023-11-10 | John James | Purchase | $1,001 - $15,000 |
| 2023-10-31 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-10-24 | Greg Stanton | Sale (Full) | $1,001 - $15,000 |
| 2023-10-10 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-10-02 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-09-26 | Greg Stanton | Purchase | $1,001 - $15,000 |
| 2023-09-13 | Michael C. Burgess | Sale (Full) | $1,001 - $15,000 |
| 2023-09-11 | Scott Franklin | Sale (Partial) | $15,001 - $50,000 |
| 2023-09-08 | Lois Frankel | Sale (Full) | $1,001 - $15,000 |
| 2023-09-06 | Lois Frankel | Sale (Partial) | $1,001 - $15,000 |
| 2023-09-06 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-09-01 | Jared Moskowitz | Purchase | $1,001 - $15,000 |
| 2023-08-29 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2023-08-03 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2023-08-02 | Lois Frankel | Sale (Partial) | $1,001 - $15,000 |
| 2023-07-14 | Jared Moskowitz | Purchase | $1,001 - $15,000 |
| 2023-07-14 | Daniel Goldman | Sale (Full) | $1,001 - $15,000 |
| 2023-07-12 | Daniel Goldman | Sale (Full) | $1,001 - $15,000 |
| 2023-06-29 | Ro Khanna | Sale | $50,001 - $100,000 |
| 2023-06-28 | Lois Frankel | Sale (Partial) | $1,001 - $15,000 |
| 2023-06-26 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2021-03-10 | Rick Allen | Sale (Full) | $15,001 - $50,000 |
| 2020-07-02 | Rick Allen | Purchase | $15,001 - $50,000 |
| 2017-11-30 | Rick Allen | Sale (Full) | $1,001 - $15,000 |
Signal
Neutral signalScored 2026-10-27 Drivers: Congress, trend, fundamentals. Moteurs : Congrès, tendance, fondamentaux.
MRK combines solid financial health (strong ~28% net margins, healthy cash flow) with a meaningful oncology catalyst in sacituzumab tirumotecan's Phase III data showing a 32% reduction in death risk in endometrial…
The first sentence of the analysis written for MRK on 2026-10-27 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Neutral signal
Drivers: Congress, trend, fundamentals. Moteurs : Congrès, tendance, fondamentaux.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Narrative Supports a bullish reading. Stored narrative reading is in the bullish band
- Congress Pulls against a bullish reading. STOCK Act sale disclosures outnumber purchases
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Supports a bullish reading. Current ratio 1.54 · operating margin 36%
Suggested stop 139.25, nearest stored support minus 0.5 ATR(1.8% under the last close). Reward/risk to the next stored resistance is 5.15. Research, not advice. Not an order.
Recent news
- 2026-10-26 Merck Highlights Phase III Cancer Wins, Eyes 2027 Oncology Pipeline Catalysts Merck & Co., Inc. NYSE: MRK outlined new oncology data and development plans at the European Society for Medical Oncology annual meeting, highlighting phase III results for its sacituzumab tirumotecan, or sac-TMT, antibody-drug conjugate in endometrial cancer and its individualized neoantigen therapy, intismeran autogene, in melanoma.
- 2026-10-26 Merck & Co., Inc. (MRK) Shareholder/Analyst Call Transcript Merck & Co., Inc. (MRK) Shareholder/Analyst Call Transcript
- 2026-10-26 Moderna''s Rally May Have Run Out of Steam. Here''s What to Watch Next Moderna''s stock has taken a big hit that could signal the end of this year''s cancer vaccine-driven rally. It may not be too late to play the forces behind its rise.
- 2026-10-26 Data about Merck and Moderna Melanoma Vaccine Leaks Out Leaked data from Moderna and Merck''s highly anticipated melanoma vaccine trial has led to a rare disconnect between doctors, who celebrated the result, and Wall Street, which sold off the stocks. Normally results of such pivotal drug studies are binary, with doctors, patients and investors all learning whether a novel medicine will make a meaningful difference in people''s lives and forming the same conclusion.
- 2026-10-26 Which Pharmaceutical ETF Is the Better Buy: iShares’ Domestic IHE or VanEck’s Global PPH? IHE has outperformed recently by concentrating in U.S. drugmakers. PPH offers global reach and a higher dividend for investors willing to trade some of that momentum for income.
- 2026-10-26 Sacituzumab Tirumotecan (Sac-TMT) Reduced the Risk of Death by 32% and the Risk of Disease Progression or Death by 41% Compared to Chemotherapy in Certain Patients With Advanced or Recurrent Endometrial Cancer RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Sac-TMT Reduced the Risk of Death by 32% and the Risk of Disease Progression or Death by 41% Compared to Chemotherapy in TroFuse-005 Trial.
- 2026-10-26 LLY vs. MRK: Which Stock Offers the More Compelling Investment Case? Lilly and Merck boast blockbuster drugs, expanding pipelines and new growth opportunities but pricing pressure, patent risks & competition shape their outlooks.
- 2026-10-26 Countdown to Merck (MRK) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS Get a deeper insight into the potential performance of Merck (MRK) for the quarter ended September 2026 by going beyond Wall Street''s top-and-bottom-line estimates and examining the estimates for some of its key metrics.
- 2026-10-26 Earn 12-15% Potential Income: Monthly Options Series (Nov. 2026) Selling options can generate 12-15% annual income but requires discipline, risk management, and due diligence. We will discuss how to formulate a sustainable and repeatable income strategy for options. The PUT list emphasizes high-momentum stocks, while the BUY-WRITE CALL list prioritizes high dividend safety and quality scores for risk mitigation.
- 2026-10-26 Breakfast News: Science Strikes Back at Cancer Cancer trial data shines at ESMO 2026, earnings flood after tough market week, and more…
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 72.0% | 76.3% | 73.2% | 70.6% | 72.0% | |
| Ebit Margin | 34.5% | 33.0% | 5.0% | 29.4% | 30.2% | |
| Ebitda Margin | 43.5% | 40.1% | 11.5% | 36.0% | 36.8% | |
| Operating Profit Margin | 36.2% | 31.5% | 4.9% | 30.8% | 27.1% | |
| Pretax Profit Margin | 32.4% | 31.1% | 3.1% | 27.7% | 28.5% | |
| Continuous Operations Profit Margin | 28.1% | 26.7% | 0.6% | 24.5% | 25.4% | |
| Net Profit Margin | 28.1% | 26.7% | 0.6% | 24.5% | 26.8% | |
| Bottom Line Profit Margin | 28.1% | 26.7% | 0.6% | 24.5% | 26.8% | |
| Current Ratio | 1.536 | 1.365 | 1.252 | 1.474 | 1.268 | |
| Quick Ratio | 1.301 | 1.150 | 1.005 | 1.230 | 1.018 | |
| Solvency Ratio | 0.286 | 0.306 | 0.061 | 0.292 | 0.241 | |
| Cash Ratio | 0.514 | 0.466 | 0.266 | 0.524 | 0.339 | |
| Price To Earnings Ratio | 14.419 | 14.716 | 778.714 | 19.363 | 14.853 | |
| Price To Earnings Growth Ratio | 1.805 | 0.003 | -7.982 | 1.753 | 0.175 | |
| Forward Price To Earnings Growth Ratio | 1.805 | 0.003 | -7.982 | 1.753 | 0.175 | |
| Price To Earnings Diluted Ratio | 14.459 | 14.760 | 778.714 | 19.431 | 14.911 | |
| Price To Earnings Diluted Growth Ratio | 1.805 | 0.003 | -7.983 | 1.752 | 0.176 | |
| Price To Book Ratio | 5.006 | 5.439 | 7.389 | 6.108 | 5.078 | |
| Price To Sales Ratio | 4.056 | 3.925 | 4.619 | 4.739 | 3.981 | |
| Price To Free Cash Flow Ratio | 21.307 | 13.919 | 30.370 | 19.101 | 20.070 | |
| Price To Operating Cash Flow Ratio | 15.988 | 11.733 | 21.350 | 14.712 | 13.743 | |
| Debt To Assets Ratio | 0.369 | 0.327 | 0.340 | 0.293 | 0.328 | |
| Debt To Equity Ratio | 0.961 | 0.826 | 0.965 | 0.695 | 0.907 | |
| Debt To Capital Ratio | 0.490 | 0.452 | 0.491 | 0.410 | 0.476 | |
| Long Term Debt To Capital Ratio | 0.471 | 0.427 | 0.473 | 0.385 | 0.446 | |
| Financial Leverage Ratio | 2.602 | 2.529 | 2.839 | 2.374 | 2.768 | |
| Working Capital Turnover Ratio | 5.082 | 7.623 | 6.695 | 6.632 | 14.260 | |
| Operating Cash Flow Ratio | 0.581 | 0.755 | 0.506 | 0.788 | 0.591 | |
| Operating Cash Flow Sales Ratio | 0.254 | 0.335 | 0.216 | 0.322 | 0.290 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.750 | 0.843 | 0.703 | 0.770 | 0.685 | |
| Debt Service Coverage Ratio | 6.004 | 5.843 | 2.143 | 6.670 | 5.089 | |
| Interest Coverage Ratio | 17.307 | 15.910 | 2.578 | 19.004 | 16.376 | |
| Short Term Operating Cash Flow Coverage Ratio | 5.713 | 8.104 | 9.480 | 9.812 | 5.850 | |
| Operating Cash Flow Coverage Ratio | 0.326 | 0.561 | 0.359 | 0.597 | 0.407 | |
| Capital Expenditure Coverage Ratio | 4.006 | 6.367 | 3.367 | 4.352 | 3.172 | |
| Dividend Paid And Capex Coverage Ratio | 1.340 | 1.915 | 1.150 | 1.675 | 1.276 | |
| Dividend Payout Ratio | 0.448 | 0.458 | 20.397 | 0.483 | 0.507 | |
| Enterprise Value Multiple | 10.591 | 10.772 | 44.462 | 14.085 | 12.315 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 72.0% | ▼-4.3% | ▼-0.9% |
| Ebit Margin | 34.5% | ▲1.5% | ▲8.1% |
| Ebitda Margin | 43.5% | ▲3.5% | ▲10.0% |
| Operating Profit Margin | 36.2% | ▲4.7% | ▲10.1% |
| Pretax Profit Margin | 32.5% | ▲1.4% | ▲7.9% |
| Continuous Operations Profit Margin | 28.1% | ▲1.4% | ▲7.1% |
| Net Profit Margin | 28.1% | ▲1.4% | ▲6.8% |
| Bottom Line Profit Margin | 28.1% | ▲1.4% | ▲6.8% |
| Current Ratio | 1.536 | ▲0.172 | ▲0.157 |
| Quick Ratio | 1.301 | ▲0.151 | ▲0.160 |
| Solvency Ratio | 0.286 | ▼-0.019 | ▲0.049 |
| Cash Ratio | 0.514 | ▲0.048 | ▲0.092 |
| Price To Earnings Ratio | 14.419 | ▼-0.297 | ▼-153.994 |
| Price To Earnings Growth Ratio | 1.805 | ▲1.802 | ▲2.654 |
| Forward Price To Earnings Growth Ratio | 1.805 | ▲1.802 | ▲2.654 |
| Price To Earnings Diluted Ratio | 14.459 | ▼-0.301 | ▼-153.996 |
| Price To Earnings Diluted Growth Ratio | 1.805 | ▲1.802 | ▲2.654 |
| Price To Book Ratio | 5.006 | ▼-0.432 | ▼-0.798 |
| Price To Sales Ratio | 4.056 | ▲0.131 | ▼-0.208 |
| Price To Free Cash Flow Ratio | 21.308 | ▲7.388 | ▲0.354 |
| Price To Operating Cash Flow Ratio | 15.988 | ▲4.255 | ▲0.483 |
| Debt To Assets Ratio | 0.369 | ▲0.042 | ▲0.038 |
| Debt To Equity Ratio | 0.961 | ▲0.134 | ▲0.090 |
| Debt To Capital Ratio | 0.490 | ▲0.037 | ▲0.026 |
| Long Term Debt To Capital Ratio | 0.470 | ▲0.044 | ▲0.030 |
| Financial Leverage Ratio | 2.602 | ▲0.073 | ▼-0.020 |
| Working Capital Turnover Ratio | 5.082 | ▼-2.541 | ▼-2.976 |
| Operating Cash Flow Ratio | 0.582 | ▼-0.174 | ▼-0.063 |
| Operating Cash Flow Sales Ratio | 0.254 | ▼-0.081 | ▼-0.030 |
| Free Cash Flow Operating Cash Flow Ratio | 0.750 | ▼-0.093 | ▲0.000 |
| Debt Service Coverage Ratio | 6.004 | ▲0.162 | ▲0.854 |
| Interest Coverage Ratio | 17.307 | ▲1.398 | ▲3.072 |
| Short Term Operating Cash Flow Coverage Ratio | 5.713 | ▼-2.391 | ▼-2.078 |
| Operating Cash Flow Coverage Ratio | 0.326 | ▼-0.235 | ▼-0.124 |
| Capital Expenditure Coverage Ratio | 4.006 | ▼-2.361 | ▼-0.247 |
| Dividend Paid And Capex Coverage Ratio | 1.341 | ▼-0.574 | ▼-0.131 |
| Dividend Payout Ratio | 0.448 | ▼-0.010 | ▼-4.011 |
| Enterprise Value Multiple | 10.591 | ▼-0.181 | ▼-7.854 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $263.36B | $251.88B | $277.67B | $280.93B | $193.90B | |
| Enterprise value | $299.33B | $276.91B | $307.10B | $300.22B | $220.43B | |
| EV / Sales | 4.61x | 4.32x | 5.11x | 5.06x | 4.53x | |
| EV / Op. cash flow | 18.17x | 12.90x | 23.61x | 15.72x | 15.62x | |
| EV / Free cash flow | 24.22x | 15.30x | 33.59x | 20.41x | 22.82x | |
| EV / EBITDA | 10.59x | 10.77x | 44.46x | 14.09x | 12.31x | |
| Net debt / EBITDA | 1.27x | 0.97x | 4.26x | 0.91x | 1.48x | |
| Current ratio | 1.54x | 1.36x | 1.25x | 1.47x | 1.27x | |
| Income quality | 0.90x | 1.25x | 35.63x | 1.31x | 1.14x | |
| Graham number | $59 | $53 | $7 | $48 | $42 | |
| Graham net-net | -$23 | -$18 | -$20 | -$16 | -$20 | |
| Tax burden | 86.6% | 85.9% | 19.3% | 88.3% | 94.0% | |
| Interest burden | 93.9% | 94.0% | 62.2% | 94.5% | 94.5% | |
| Working capital | $15.19B | $10.36B | $6.47B | $11.48B | $6.39B | |
| Invested capital | $90.27B | $72.18B | $68.73B | $74.38B | $69.87B | |
| Return on assets | 13.3% | 14.6% | 0.3% | 13.3% | 12.3% | |
| Operating ROA | 18.5% | 18.1% | 2.7% | 17.0% | 13.4% | |
| Return on tangible assets | 20.6% | 21.6% | 0.5% | 21.5% | 21.2% | |
| Return on equity | 34.7% | 37.0% | 1.0% | 31.6% | 34.2% | |
| Return on invested capital | 18.3% | 19.0% | 0.7% | 18.5% | 13.9% | |
| Return on capital employed | 21.6% | 22.8% | 3.6% | 21.5% | 16.1% | |
| Earnings yield | 6.9% | 6.8% | 0.1% | 5.2% | 6.7% | |
| Free cash flow yield | 4.7% | 7.2% | 3.3% | 5.2% | 5.0% | |
| Capex / Op. cash flow | 25.0% | 15.7% | 29.7% | 23.0% | 31.5% | |
| Capex / Depreciation | 70.4% | 74.9% | 99.8% | 112.3% | 138.4% | |
| Capex / Sales | 6.3% | 5.3% | 6.4% | 7.4% | 9.1% | |
| SG&A / Sales | 16.5% | 15.7% | 16.4% | 16.3% | 19.3% | |
| R&D / Sales | 19.3% | 28.0% | 50.8% | 22.9% | 25.1% | |
| Stock comp / Sales | 0.0% | 1.2% | 1.1% | 0.9% | 1.0% | |
| Intangibles / Total assets | 35.3% | 32.5% | 36.8% | 38.0% | 41.8% | |
| Days sales outstanding | 71d | 58d | 63d | 58d | 69d | |
| Days payables outstanding | 88d | 98d | 89d | 89d | 123d | |
| Operating cycle | 205d | 205d | 207d | 182d | 229d | |
| Cash conversion cycle | 116d | 107d | 118d | 93d | 105d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+4.6%EV / Sales ▲+6.8%EV / EBITDA ▼-1.7%EV / Op. cash flow ▲+5.273Earnings yield ▲+0.001Graham number ▲+6.003
Profitability
Return on equity ▼-0.023Return on assets ▼-0.013Return on invested capital ▼-0.007Return on capital employed ▼-0.012Operating ROA ▲+0.004Income quality ▼-0.351Tax burden ▲+0.008
Efficiency
Days sales outstanding ▲+12.815Days payables outstanding ▼-9.649Operating cycle ▼-0.386Cash conversion cycle ▲+9.262Capex / Sales ▲+0.011R&D / Sales ▼-0.087
Balance-sheet strength
Current ratio ▲+0.172Net debt / EBITDA ▲+0.299Working capital ▲+4827000000.000Invested capital ▲+18093000000.000Intangibles / Total assets ▲+0.028
Change over 5 years
Valuation
Market cap ▲+35.8%EV / Sales ▲+1.9%EV / EBITDA ▼-14.0%EV / Op. cash flow ▲+2.548Earnings yield ▲+0.002Graham number ▲+16.899
Profitability
Return on equity ▲+0.005Return on assets ▲+0.010Return on invested capital ▲+0.044Return on capital employed ▲+0.055Operating ROA ▲+0.051Income quality ▼-0.239Tax burden ▼-0.074
Efficiency
Days sales outstanding ▲+2.107Days payables outstanding ▼-35.115Operating cycle ▼-23.794Cash conversion cycle ▲+11.321Capex / Sales ▼-0.028R&D / Sales ▼-0.059
Balance-sheet strength
Current ratio ▲+0.268Net debt / EBITDA ▼-0.210Working capital ▲+8795000000.000Invested capital ▲+20402000000.000Intangibles / Total assets ▼-0.066